{rfName}

Indexed in

License and Use

Icono OpenAccess

Altmetrics

Analysis of institutional authors

Prieto González, SergioAuthor

Share

March 4, 2022
Publications
>
Article

Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies

Publicated to: Clinical And Experimental Rheumatology. 40 (2): 274-283 - 2022-02-01 40(2), DOI: 10.55563/clinexprheumatol/di1083

Authors:

Cavagna, L; Meloni, F; Meyer, A; Sambataro, G; Belliato, M; De Langhe, E; Cavazzana, I; Pipitone, N; Triantafyllias, K; Mosca, M; Barsotti, S; Zampogna, G; Biglia, A; Emmi, G; de Visser, M; van der Kooi, A; Parronchi, P; Hirschi, S; da Silva, JAP; Scirè, CA; Furini, F; Giannini, M; Gonzalez, OM; Damian, L; Piette, Y; Smith, V; Mera-Varela, A; Bachiller-Corral, J; Rodriguez, IC; Brandy-Garcia, AM; Maurier, F; Perrin, J; Gonzalez-Moreno, J; Drott, U; Delbruck, C; Schwarting, A; Arrigoni, E; Sebastiani, GD; Iuliano, A; Nannini, C; Quartuccio, L; Cambron, ABR; Cañamero, MAB; Blanco, IV; Cagnotto, G; Pesci, A; Luppi, F; Dei, G; Bueno, FIR; Franceschini, F; Chiapparoli, I; Zanframundo, G; Lettieri, S; De Stefano, L; Cutolo, M; Mathieu, A; Piga, M; Prieto-González, S; Moraes-Fontes, MF; Fonseca, JE; Jovani, V; Riccieri, V; Santaniello, A; Montefort, S; Bilocca, D; Erre, GL; Bartoloni, E; Gerli, R; Monti, MC; Lorenz, HM; Sambataro, D; Randone, SB; Schneider, U; Valenzuela, C; Lopez-Mejias, R; Cifrian, J; Mejia, M; Perez, MIG; Wendel, S; Fornaro, M; De Luca, G; Orsolini, G; Rossini, M; Dieude, P; Knitza, J; Castañeda, S; Voll, RE; Rojas-Serrano, J; Valentini, A; Vancheri, C; Matucci-Cerinic, M; Feist, E; Codullo, V; Iannone, F; Distler, JH; Montecucco, C; Gonzalez-Gay, MA
[+]

Affiliations

Amsterdam Univ Med Ctr, Neurol, Amsterdam, Netherlands - Author
AO Spedali Civili, Brescia, Italy - Author
Artroreuma Srl, Outpatient Rheumatol, Mascalucia, Italian Natl Hlth Syst, Catania, Italy - Author
Azienda Osped Brunico, Rheumatol, Brunico, Italy - Author
Azienda Osped Univ Cagliari, Cagliari, Italy - Author
Azienda Osped Univ Careggi, Rheumatol, Florence, Italy - Author
Azienda Osped Univ Catania, Pulmonol, Catania, Italy - Author
Azienda Osped Univ Pisana, Rheumatol, Pisa, Italy - Author
Azienda Osped Univ S Anna, Rheumatol, Ferrara, Italy - Author
Azienda Osped Univ Sassari, Rheumatol, Sassari, Italy - Author
Charite Univ Med Berlin, Rheumatol, Berlin, Germany - Author
Complejo Hosp Salamanca, Rheumatol, Salamanca, Spain - Author
Ctr Hosp & Univ Coimbra, Rheumatol, Coimbra, Portugal - Author
Ctr Rheumat Dis, Rheumatol, Bad Kreuznach, Germany - Author
Emergency Cty Teaching Hosp, Rheumatol, Cluj Napoca, Romania - Author
Fdn IRCCS Ca Granda Osped Maggiore Policlin, Scleroderma Unit, Milan, Italy - Author
Fdn IRCCS Policlin S Matteo, UOC Anestesia & Rianimazione Cardiopolmonare 2, Pavia, Italy - Author
Ghent Univ Hosp, Dept Rheumatol, Ghent, Belgium - Author
Goethe Univ Frankfurt, Rheumatol, Frankfurt, Germany - Author
Heidelberg Univ, Rheumatol, Heidelberg, Germany - Author
Hop Belle Ile, HPMetz, Pneumol, Metz, France - Author
Hop Belle Ile, HPMetz, Rheumatol, Metz, France - Author
Hop Univ Strasbourg, Ctr Reference Malad Autoimmunes Rares, Serv Physiol & Explorat Fonctionnelles Musculaire, Rheumatol, Rheumatology, France - Author
Hosp Clin Barcelona, Internal Med, Barcelona, Spain - Author
Hosp Clin Univ Santiago de Compostela, Rheumatol, Santiago, Spain - Author
Hosp Univ Ramon Y Cajal, Rheumatol, Madrid, Spain - Author
Hosp Univ Rio Hortega, Rheumatol, Valladolid, Spain - Author
Hosp Univ San Augustin, Rheumatol, Aviles, Spain - Author
Hosp Univ Son Llatzer, Internal Med Dept, Rheumatol, Palma De Mallorca, Spain - Author
Inst Nacl Enfermedades Resp, Interstitial Lung Dis Unit, Mexico City, DF, Mexico - Author
Inst Nacl Enfermedades Resp, Pneumol Unit, Mexico City, DF, Mexico - Author
Inst Nacl Enfermedades Resp, Rheumatol Unit, Mexico City, DF, Mexico - Author
IRCCS Policlin S Matteo Fdn, Radiol, Pavia, Italy - Author
IRCCS Policlin S Matteo Fdn, Via Golgi 19, I-27100 Pavia, Italy - Author
IRCCS San Matteo Fdn, Transplant Ctr Unit, Pavia, Italy - Author
Johannes Gutenberg Univ Mainz, Rheumatol, Mainz, Germany - Author
Mater Dei Hosp, Pneumol, Msida, Malta - Author
Osped Guglielmo Saliceto, Rheumatol, Piacenza, Italy - Author
Osped San Camillo, Rheumatol, Rome, Italy - Author
Policlin Umberto 1, Rome, Italy - Author
Prato Hosp, Rheumatol, Prato, Italy - Author
S Maria Hosp IRCCS, Rheumatol, Reggio Emilia, Italy - Author
Severo Ochoa Hosp, Rheumatol, Madrid, Spain - Author
Sierralana Hosp, Rheumatol, Torrellavega, Spain - Author
Skane Univ Hosp, Rheumatol, Malmo, Sweden - Author
Strasbourg Univ, Strasbourg Univ Hosp, NHC, Pneumol, Strasbourg, France - Author
Univ Autonoma, Hosp Univ La Princesa, Catedra UAM Roche EPID Future, IIS Princesa, Madrid, Spain - Author
Univ Autonoma, Hosp Univ La Princesa, Catedra UAM Roche EPID Future, IIS Princesa,Pneumol, Madrid, Spain - Author
Univ Bari, Rheumatol, Bari, Italy - Author
Univ Brescia, Rheumatol, Brescia, Italy - Author
Univ Cantabria, Hosp Univ Marques de Valdecilla, IDIVAL, Pneumol, Santander, Spain - Author
Univ Cantabria, Hosp Univ Marques de Valdecilla, IDIVAL, Rheumatol, Santander, Spain - Author
Univ Clin Cagliari, Rheumatol, Cagliari, Italy - Author
Univ Erlangen Nurnberg, Rheumatol, Erlangen, Germany - Author
Univ Firenze, Careggi Univ Hosp, Internal Interdisciplinary Unit, Lupus Clin, Florence, Italy - Author
Univ Firenze, Dept Expt & Clin Med, Florence, Italy - Author
Univ Florence, Dept Expt & Clin Med, Florence, Italy - Author
Univ Freiburg, Fac Med, Med Ctr, Rheumatol, Freiburg, Germany - Author
Univ Genoa, IRCCS San Martino, DIMI, Rheumatol, Genoa, Italy - Author
Univ Ghent, Dept Internal Med, Ghent, Belgium - Author
Univ Hosp J Diaz, Rheumatol, Madrid, Spain - Author
Univ Hosp Lisboa Norte, Rheumatol, Lisbon, Portugal - Author
Univ Hosp, Rheumatol, Alicante, Spain - Author
Univ Hosp, Rheumatol, Leuven, Belgium - Author
Univ Lisbon, Ctr Acad Med Lisboa, Fac Med, Inst Med Mol, Lisbon, Portugal - Author
Univ Lisbon, Ctr Hosp Lisboa Norte, Ctr Acad Med Lisboa, Serv Reumatol,Fac Med, Lisbon, Portugal - Author
Univ Milano Bicocca, San Gerardo Hosp, Pneumol, Monza, Italy - Author
Univ Paris Diderot, Rheumatol, Hop Bichat Claude Bernard, Paris, France - Author
Univ Pavia, Dept Publ Hlth, Biostat Unit, Pavia, Italy - Author
Univ Pavia, Pavia, Italy - Author
Univ Pavia, Pneumol, Pavia, Italy - Author
Univ Pavia, Rheumatol, Via Golgi 19, I-27100 Pavia, Italy - Author
Univ Perugia, Rheumatol, Perugia, Italy - Author
Univ Roma La Sapienza, Rheumatol, Rome, Italy - Author
Univ Udine, Acad Hosp Santa Maria della Misericordia, Dept Med DAME, Rheumatol Unit, Udine, Italy - Author
Univ Verona, Rheumatol, Verona, Italy - Author
Univ Vita Salute, Rheumatol, Milan, Italy - Author
VIB Inflammat Res Ctr IRC, Unit Mol Immunol & Inflammat, Ghent, Belgium - Author
See more

Abstract

Objective To define the clinical spectrum time-course and prognosis of non-Asian patients positive for anti-MDA5 antibodies. Methods We conducted a multicentre, international, retrospective cohort study. Results 149 anti-MDA5 positive patients (median onset age 53 years, median disease duration 18 months), mainly females (100, 67%), were included. Dermatomyositis (64, 43%) and amyopathic dermatomyositis (47, 31%), were the main diagnosis; 15 patients (10%) were classified as interstitial pneumonia with autoimmune features (IPAF) and 7 (5%) as rheumatoid arthritis. The main clinical findings observed were myositis (84, 56%), interstitial lung disease (ILD) (108, 78%), skin lesions (111, 74%), and arthritis (76, 51%). The onset of these manifestations was not concomitant in 74 cases (50%). Of note, 32 (21.5%) patients were admitted to the intensive care unit for rapidly progressive-ILD, which occurred in median 2 months from lung involvement detection, in the majority of cases (28, 19%) despite previous immunosuppressive treatment. One-third of patients (47, 32% each) was ANA and anti-ENA antibodies negative and a similar percentage was anti-Ro52 kDa antibodies positive. Non-specific interstitial pneumonia (65, 60%), organising pneumonia (23, 21%), and usual interstitial pneumonia-like pattern (14, 13%) were the main ILD patterns observed. Twenty-six patients died (17%), 19 (13%) had a rapidly progressive-ILD. Conclusion The clinical spectrum of the anti-MDA5 antibodies-related disease is heterogeneous. Rapidly-progressive ILD deeply impacts the prognosis also in non-Asian patients, occurring early during the disease course. Anti-MDA5 antibody positivity should be considered even when baseline autoimmune screening is negative, anti-Ro52 kDa antibodies are positive, and radiology findings show a NSIP pattern.
[+]

Keywords

classification criteriacollegedermatomyositisgene 5 antibodyidiopathic inflammatory myopathiesleaguerapidly progressive interstitial lung diseasesutilityvirusInterstitial lung-diseaseMelanoma differentiation-associated protein 5 antibody

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal CLINICAL AND EXPERIMENTAL RHEUMATOLOGY due to its progression and the good impact it has achieved in recent years, according to the agency Scopus (SJR), it has become a reference in its field. In the year of publication of the work, 2022, it was in position , thus managing to position itself as a Q2 (Segundo Cuartil), in the category Rheumatology. Notably, the journal is positioned en el Cuartil Q3 for the agency WoS (JCR) in the category Rheumatology.

From a relative perspective, and based on the normalized impact indicator calculated from World Citations provided by WoS (ESI, Clarivate), it yields a value for the citation normalization relative to the expected citation rate of: 4.32. This indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: ESI Nov 13, 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2026-04-06, the following number of citations:

  • WoS: 35
  • Europe PMC: 7
[+]

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2026-04-06:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 38.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 38 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 6.
  • The number of mentions on the social network Facebook: 1 (Altmetric).
  • The number of mentions on the social network X (formerly Twitter): 9 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.
[+]

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: Belgium; France; Germany; Italy; Malt; Mexico; Netherlands; Oman; Portugal; Sweden.

[+]

Awards linked to the item

this research was partially funded by FOREUM - Foundation for Research in Rheumatology (http://www.foreum.org/prg_13_myositis_transition.cfm).
[+]